Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00029523 · ClinicalTrials.gov registry record · Phase 4
DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor
A Phase 4 study, sponsored by Pacira Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT00029523 is a Phase 4 study that has completed, run by Pacira Pharmaceuticals. The registered enrollment target is 100 participants.
The verdict
NCT00029523, a Phase 4 study, has completed, sponsored by Pacira Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to find out how well an experimental drug called DepoCyt works for neoplastic meningitis (cancer that has spread to the tissues around the brain and spinal cord). DepoCyt is a new slow-release form of the cancer drug called ara-C (cytarabine). Cytarabine has been used for many years to treat cancer.
Interventions
- DRUG Intrathecal (injected into the spinal fluid) DepoCyt
- DRUG Intrathecal methotrexate
- DRUG Intrathecal cytarabine (also known as ara-C)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2001-04 |
| Est. Completion | 2004-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00029523
The ClinicalTrials.gov registry entry for NCT00029523 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pacira Pharmaceuticals, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Intrathecal (injected into the spinal fluid) DepoCyt is the first listed.
NCT00029523 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00029523 about?
NCT00029523 is a clinical study titled "DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor". The purpose of this study is to find out how well an experimental drug called DepoCyt works for neoplastic meningitis (cancer that has spread to the tissues around the brain and spinal cord). DepoCyt is a new slow-release form of the cancer drug called ara-C (cytarabine). Cytarabine has been used fo...
What is the current status of trial NCT00029523?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2001-04. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00029523?
The interventions under investigation include: Intrathecal (injected into the spinal fluid) DepoCyt (DRUG), Intrathecal methotrexate (DRUG), Intrathecal cytarabine (also known as ara-C) (DRUG).
Who is sponsoring clinical trial NCT00029523?
This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.